Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Soshnev AA, C Allis D, Cesarman E, Melnick AM. Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer. Cancer Res. 2021.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12(1):3372.

Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. Author Correction: Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021;2(11):1243.

Gjyrezi A, Galletti G, Zhang J, Worroll D, Sigouros M, Kim S, et al. Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Commun Biol. 2021;4(1):785.

Zoughbi WA, Fox J, Beg S, Papp E, Hissong E, Ohara K, et al. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Oncologist. 2021.

Fowler FC, Tyler JK. A Proximity Ligation Method to Detect Proteins Bound to Single-Stranded DNA after DNA End Resection at DNA Double-Strand Breaks. Methods Protoc. 2021;5(1).

Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.

Mavragani CP, Kirou KA, Nezos A, Seshan S, Wild T, Wahl SM, et al. Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. Clin Immunol. 2021;223:108649.

Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):5775.

Gaffney C, Liu D, Cooley V, Ma X, Angulo C, Robinson B, et al. Tumor size and genomic risk in localized prostate cancer. Urol Oncol. 2021;39(7):434.e17-434.e22.